Glioma Clinical Trials
Here are the 6 most popular medical studies for glioma
Molecular Profiling
Specialized Tumor Board Recommendation for High Grade Glioma
This trial will test a new treatment approach for children with High-grade gliomas HGG that is based on each patient's tumor gene expression, whole-exome sequencing (WES), targeted panel profile (UCSF 500 gene panel), and RNA-Seq.
CDK4/6 Inhibitor
Gemcitabine + Trametinib + Filgrastim + Sonidegib + Ribociclib for Brain Tumors
This trial will help improve cure rates for children with brain tumors by studying how the tumors continue to resist modern advances and by testing new approaches to treatment.
Popular filter options for glioma trials
Brain Tumor Clinical Trials
View 89 Brain Tumor medical studies.
Chemotherapy
PF-07799544 + Related Treatments for Advanced Solid Tumors
This trial is studying a new medicine (PF-07799544) to treat advanced solid tumors. Participants will receive the medicine and possibly other treatments. They'll be monitored by the study team during regular visits.
PARP Inhibitor
Pembrolizumab + Olaparib + Temozolomide for Glioma
This trial will test if a combo of pembrolizumab, olaparib, & temozolomide is safe & effective for people with a glioma that didn't respond to previous treatment or came back after treatment.
Astrocytoma Clinical Trials
View 77 Astrocytoma medical studies.
Chemotherapy
PF-07799544 + Related Treatments for Advanced Solid Tumors
This trial is studying a new medicine (PF-07799544) to treat advanced solid tumors. Participants will receive the medicine and possibly other treatments. They'll be monitored by the study team during regular visits.
PARP Inhibitor
Pembrolizumab + Olaparib + Temozolomide for Glioma
This trial will test if a combo of pembrolizumab, olaparib, & temozolomide is safe & effective for people with a glioma that didn't respond to previous treatment or came back after treatment.
Metastatic Glioma Clinical Trials
View 97 metastatic glioma medical studies.
Chemotherapy
PF-07799544 + Related Treatments for Advanced Solid Tumors
This trial is studying a new medicine (PF-07799544) to treat advanced solid tumors. Participants will receive the medicine and possibly other treatments. They'll be monitored by the study team during regular visits.
Radiation
Rhenium Liposome Treatment for Brain Tumor
This trial is testing a new cancer treatment to see if it is safe and effective. It uses a modified Fibonacci dose escalation, which means it starts with a small dose and increases the dose each time until the maximum tolerated dose is reached. The starting absorbed dose is 1mCi in a volume of 0.660mL.
IDH1 Positive Clinical Trials
View 6 IDH1 positive medical studies.
Small Molecule Inhibitor
Safusidenib for Brain Tumor
This trial studies the efficacy, safety, & PK of an experimental drug to treat recurrent/progressive IDH1 mutant glioma (brain cancer). It will enroll up to 60 patients in 2 parts & an exploratory surgery cohort.
Phase 3 Glioma Clinical Trials
View 97 phase 3 glioma medical studies.
Dendritic cell immunotherapy
Dendritic Cell Therapy for Glioblastoma
This trial is testing a new therapy, DCVax-L, for patients with newly diagnosed Glioblastoma (GBM) who are scheduled for surgery. The patients will receive the standard of care, including radiation and Temodar therapy, and then will be randomly assigned to also receive either DCVax-L or a placebo. All patients will have the option to receive DCVax-L after their disease progresses.
Alkylating agents
Chemotherapy + Radiation Therapy for Brain Tumor
This trial is studying giving methotrexate with combination chemotherapy and radiation therapy to young patients with newly diagnosed gliomas to see if it is more effective than combination chemotherapy and radiation therapy alone.
Histone Deacetylase Inhibitor
Vorinostat + Temozolomide + Bevacizumab for Brain Tumor
This trial is testing vorinostat, temozolomide, or bevacizumab to see which is more effective when given with radiation therapy to treat high-grade glioma in young patients.
Glioma Clinical Trials With No Placebo
View 97 glioma medical studies that do not have a placebo group.
Chemotherapy
PF-07799544 + Related Treatments for Advanced Solid Tumors
This trial is studying a new medicine (PF-07799544) to treat advanced solid tumors. Participants will receive the medicine and possibly other treatments. They'll be monitored by the study team during regular visits.
PARP Inhibitor
Pembrolizumab + Olaparib + Temozolomide for Glioma
This trial will test if a combo of pembrolizumab, olaparib, & temozolomide is safe & effective for people with a glioma that didn't respond to previous treatment or came back after treatment.
View More Glioma Trials
See another 66 many medical studies focused on glioma.
Frequently Asked Questions
Introduction to glioma
What are the top hospitals conducting glioma research?
In the battle against glioma, a formidable type of brain tumor, several hospitals are leading the charge in groundbreaking clinical trials. Washington University School of Medicine in Saint Louis takes center stage with an impressive 12 active glioma trials and a remarkable history of 56 completed trials since their first recorded experiment back in 1998. Meanwhile, Children's National Medical Center in Washington D.C., known for its expertise in pediatric care, is making significant strides with nine ongoing glioma trials and a notable record of conducting 68 trials dedicated to this challenging condition since their inaugural investigation in 2001.
Boston's Dana-Farber Cancer Institute joins the ranks as well, contributing heavily to glioma research with nine active clinical trials and an admirable tally of 74 previously conducted studies dating back to their pioneering trial in 1997. Across state lines at Memorial Sloan Kettering Cancer Center located in New York City, researchers are hard at work conducting nine ongoing glioma trials while having accomplished an impressive total of 58 previous investigations since initiating their first study on this complex brain tumor subtype in 2002.
Lastly but certainly not least important is Cincinnati Children's Hospital Medical Center situated within Ohio; although smaller-scale compared to some counterparts mentioned earlier they play vital roles too - currently hosting seven active glioma clinical tests while also holding solid contribution through fifty-seven prior experiments starting from same timeline i.e. year2002.
These institutions embody hope for patients battling against the challenges presented by gliomas while actively paving new paths towards improved treatments and ultimately a cure. Their dedication to understanding this devastating disease brings us closer each day towards breakthroughs that promise brighter futures for those affected by these aggressive brain tumors worldwide
Which are the best cities for glioma clinical trials?
When it comes to glioma clinical trials, several cities emerge as leading hubs for cutting-edge research. New York City takes the lead with 36 active trials focusing on treatments like PF-07799933 and Bevacizumab. Houston, Texas follows closely behind with 29 ongoing studies exploring interventions such as ONC201 Once Weekly Group and AG881. Los Angeles, California. New Yo to glioma clinical trials, several cities emerge as leading hubs for cutting-edge research. New York City takes the lead with 36 active trials focusing on treatments like PF-07799933 and Bevacizumab. Houston, Texas follows closely behind with 29 ongoing studies exploring interventions such as ONC201 Once Weekly Group and AG881. Los Angeles, California is also a prominent city for glioma clinical trials, offering 28 active studies investigating options like Subprotocol C2 and AG-120. Each of these cities provides individuals with glioma access to a diverse range of innovative clinical trials that strive to advance treatment options and improve outcomes.
Which are the top treatments for glioma being explored in clinical trials?
Glioma research is at the forefront of medical investigations, with several promising treatments currently being explored in clinical trials. Leading the charge is pembrolizumab, which has shown potential in two active trials and six all-time glioma trials since its introduction in 2015. Another contender making waves is retifanlimab, engaged in two ongoing trials after its listing last year. Nivolumab joins the race with impressive results from two active trials and a total of 15 all-time glioma trials since 2015. Finally, AG-120 enters the scene with two active glioma trials under its belt since it was introduced back in 2014. The progress made through these clinical trials brings hope to patients battling this challenging disease as researchers strive towards finding effective treatment options for gliomas worldwide
What are the most recent clinical trials for glioma?
Recent clinical trials have brought renewed hope for patients with glioma, a type of brain tumorh glioma, a type of brain tumor. One notable trial is focused on APG-157, which has entered Phase 1 and Phase 2 studies as of September 15, 2023. Another promising development involves safusidenib at a dose of 500mg bid in a Phase 2 trial that commenced on May 26, 2023. Additionally, the combination of abemaciclib and temozolomide is being evaluated in Phase 1 trials since April7,2023. Other studies include surgical resection coupled with pharmacodynamic assays and methimazole in their investigation (Phase2), starting from January30th ,2023; and ONC201 Once Weekly Group (Phase3) commencing from January23rd ,2023.
What glioma clinical trials were recently completed?
Several recent clinical trials have made significant strides in the field of glioma research, offering new hope for patients battling this challenging brain cancer. In November 2020, Dana-Farber Cancer of glioma research, offering new hope for patients battling this challenging brain cancer. In November 2020, Dana-Farber Cancer Institute concluded a successful trial investigating Perampanel's potential as a treatment option. Prelude Therapeutics also completed their PRT811 trial in November 2019, while James Mountz wrapped up their study on 18F-fluciclovine in October 2019. These advancements highlight the ongoing dedication of researchers and institutions to finding effective therapies against glioma.